Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anxiety
Biotech
Vistagen lays off 20% of staff to focus on anxiety candidate
The cuts are meant to preserve cash as the biotech proceeds with another trial of fasedienol, following a recent phase 3 fail.
Darren Incorvaia
Mar 12, 2026 1:16pm
AtaiBeckley's MDMA drug improves anxiety in ph. 2 trial
Feb 26, 2026 1:32pm
Vistagen's social anxiety disorder asset stumbles in phase 3
Dec 17, 2025 2:44pm
Neuphoria nixes social anxiety program after phase 3 flop
Oct 21, 2025 10:44am
Seaport loads $225M for Karuna vets' voyage to milestones
Oct 21, 2024 8:05am
Karuna's captains set sail in new neuropsychiatric biotech
Apr 9, 2024 8:25am
